Krystal Biotech, Inc. (KRYS)
KRYS Stock Price Chart
Explore Krystal Biotech, Inc. interactive price chart. Choose custom timeframes to analyze KRYS price movements and trends.
KRYS Company Profile
Discover essential business fundamentals and corporate details for Krystal Biotech, Inc. (KRYS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Sept 2017
Employees
275.00
Website
https://www.krystalbio.comCEO
Krish S. Krishnan
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
KRYS Financial Timeline
Browse a chronological timeline of Krystal Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $1.04, while revenue estimate is $93.72M.
Earnings released on 4 Aug 2025
EPS came in at $1.29 surpassing the estimated $1.08 by +19.44%, while revenue for the quarter reached $96.04M , beating expectations by +0.66%.
Earnings released on 6 May 2025
EPS came in at $1.20 falling short of the estimated $1.38 by -13.04%, while revenue for the quarter reached $88.18M , missing expectations by -16.79%.
Earnings released on 19 Feb 2025
EPS came in at $1.52 surpassing the estimated $1.29 by +17.83%, while revenue for the quarter reached $91.14M , missing expectations by -0.23%.
Earnings released on 4 Nov 2024
EPS came in at $0.91 surpassing the estimated $0.90 by +1.11%, while revenue for the quarter reached $83.84M , missing expectations by -8.18%.
Earnings released on 5 Aug 2024
EPS came in at $0.86 surpassing the estimated $0.50 by +72.00%, while revenue for the quarter reached $70.28M , beating expectations by +7.58%.
Earnings released on 6 May 2024
EPS came in at $0.03 falling short of the estimated $0.15 by -80.00%, while revenue for the quarter reached $45.25M , missing expectations by -4.58%.
Earnings released on 26 Feb 2024
EPS came in at $0.30 surpassing the estimated -$0.38 by +178.95%, while revenue for the quarter reached $42.14M , beating expectations by +44.52%.
Earnings released on 6 Nov 2023
EPS came in at -$0.67 surpassing the estimated -$1.10 by +39.09%, while revenue for the quarter reached $8.56M , missing expectations by -70.06%.
Earnings released on 7 Aug 2023
EPS came in at -$1.25 falling short of the estimated -$0.42 by -197.62%.
Earnings released on 8 May 2023
EPS came in at -$1.76 falling short of the estimated -$1.41 by -24.82%.
Earnings released on 27 Feb 2023
EPS came in at -$1.25 surpassing the estimated -$1.39 by +10.07%.
Earnings released on 7 Nov 2022
EPS came in at -$1.17 surpassing the estimated -$1.23 by +4.88%.
Earnings released on 8 Aug 2022
EPS came in at -$1.10 falling short of the estimated -$1.08 by -1.85%.
Earnings released on 9 May 2022
EPS came in at -$0.99 falling short of the estimated -$0.96 by -3.13%.
Earnings released on 28 Feb 2022
EPS came in at -$0.94 falling short of the estimated -$0.76 by -23.68%.
Earnings released on 8 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%.
Earnings released on 9 Aug 2021
EPS came in at -$0.74 matching the estimated -$0.74.
Earnings released on 10 May 2021
EPS came in at -$0.74 falling short of the estimated -$0.55 by -34.55%.
Earnings released on 1 Mar 2021
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%.
Earnings released on 9 Nov 2020
EPS came in at -$0.49 falling short of the estimated -$0.44 by -11.36%.
KRYS Stock Performance
Access detailed KRYS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.